A multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors-Reference-Cited by-同舟云学术

A multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors

Published:2018-12-22 Issue:5 Volume:24 Page:575-582
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Isohashi Fumiaki^ORCID,Takano Tadao,Onuki Mamiko,Arimoto Takahide,Kawamura Naoki,Hara Ryusuke,Kawano Yoshiaki,Ota Yukinobu,Inokuchi Haruo,Shinjo Hidenori,Saito Toshiaki,Fujiwara Satoe,Sawasaki Takashi,Ando Ken,Horie Koji,Okamoto Hiroyuki,Murakami Naoya,Hasumi Yoko,Kasamatsu Takahiro,Toita Takafumi

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-018-01380-z.pdf

Reference23 articles.

1. Peters WA III, Liu PY, Barrett RJ II et al (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606–1613

2. Sehouli J, Runnenbaum IB, Fotopoulou C et al (2012) A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. Ann Oncol 23:2259–2264

3. Pu J. Qin SS, Ding JX et al (2013) A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical hysterectomy. J Cancer Res Clin Oncol 139:703–708

4. Klopp AH, Yeung AR, Deshmukh S et al (2018) Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203. J Clin Oncol 36:2538–2544

5. Rose PG, Ali S, Watkins E et al (2007) Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:2804–2810

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exosome-delivered circRNA circSYT15 contributes to cisplatin resistance in cervical cancer cells through the miR-503-5p/RSF1 axis;Cell Cycle;2023-10-18

2. The effect of radiotherapy time and dose on acute hematologic toxicity during concurrent postoperative chemoradiotherapy for early high-risk cervical cancer;Journal of Cancer;2023

3. Age-Dependent Hematologic Toxicity Profiles and Prognostic Serologic Markers in Postoperative Radiochemotherapy Treatment for Uterine Cervical Cancer;Technology in Cancer Research & Treatment;2022-01

4. Clinical Implication of Simultaneous Intensity-modulated Radiotherapy Boost to Tumor Bed for Cervical Cancer with Full-thickness Stromal Invasion;The Oncologist;2022-01-01

5. Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer;Cancer;2021-05